Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression - Aix-Marseille Université Access content directly
Journal Articles iScience Year : 2021

Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression

Abstract

Metabolic heterogeneity within the tumor microenvironment promotes cancer cell growth and immune suppression. We determined the impact of mitochondria-targeted complex I inhibitors (Mito-CI) in melanoma. Mito-CI decreased mitochondria complex I oxygen consumption, Akt-FOXO signaling, blocked cell cycle progression, melanoma cell proliferation and tumor progression in an immune competent model system. Immune depletion revealed roles for T cells in the antitumor effects of Mito-CI. While Mito-CI preferentially accumulated within and halted tumor cell proliferation, it also elevated infiltration of activated effector T cells and decreased myeloid-derived suppressor cells (MDSC) as well as tumor-associated macrophages (TAM) in melanoma tumors in vivo. Anti-proliferative doses of Mito-CI inhibited differentiation, viability, and the suppressive function of bone marrow-derived MDSC and increased proliferation-independent activation of T cells. These data indicate that targeted inhibition of complex I has synchronous effects that cumulatively inhibits melanoma growth and promotes immune remodeling.
Fichier principal
Vignette du fichier
pub1mica2021.pdf (4.12 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-03627837 , version 1 (01-04-2022)

Licence

Identifiers

Cite

Mahmoud Abueid, Donna Mcallister, Laura Mcolash, Megan Harwig, Gang Cheng, et al.. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience, 2021, 24 (6), pp.102653. ⟨10.1016/j.isci.2021.102653⟩. ⟨hal-03627837⟩
19 View
34 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More